Active cancer and cardiac surgery: Possible scenarios in patient decision-making
Heart disease and cancer are often found simultaneously in the same patient, and may require cardiac and non-cardiac surgery. Cancer may be part of the past medical history; in other cases the presence of an active malignancy makes the clinical management more complex. No general evidence-based recommendations are available to help in the decision-making process. Because of the lack of specific guidelines we provided a series of possible scenarios describing not unusual cases. We focused on cases where the concomitant presence of heart disease and active malignancies involved a multidisciplinary team. Four real patients with active cancer referred to our Center were assessed. Three of them had valve disease requiring cardiac surgery. Defining the timing of surgery and choosing the surgical approach required a careful and comprehensive evaluation. In the last case, the complicated balance between the thrombotic and the hemorrhagic risk involved difficult decision. Several critical points, which characterized the management of this kind of patients, were identified. In particular, the hemodynamic status, the type and stage of the tumor, the need for cancer therapy, as well as the comorbidities of the patient, had to be taken into account. This narrative review shows the importance of submitting every challenging case to the assessment of a multidisciplinary team, which involves different clinical figures, in order to guarantee the most comprehensive evaluation. When clinical management deviates from the general recommendations, an individualized approach should be used.
Carrascal Y, Gualis J, Arévalo A, et al. Cardiac surgery with extracorporeal circulation in cancer patients: Influence on surgical morbidity and mortality, and on survival. Rev Española Cardiol (English Ed. 2008).
Lorusso R, Vizzardi E, Johnson DM, et al. Cardiac surgery in adult patients with remitted or active malignancies: A review of preoperative screening, surgical management and short-and long-term postoperative results. Eur J Cardio-thoracic Surg 2018.
Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010.
Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy. J Am Coll Cardiol 2009.
Chan J, Rosenfeldt F, Chaudhuri K, Marasco S. Cardiac surgery in patients with a history of malignancy: Increased complication rate but similar mortality. Hear Lung Circ 2012.
Mistiaen WP, Van Cauwelaert P, Muylaert P, et al. Effect of prior malignancy on survival after cardiac surgery. Ann Thorac Surg 20047.
Eagle KA, Ginsburg GS, Musunuru K, et al. Identifying patients at high risk of a cardiovascular event in the near future: Current status and future directions: Report of a national heart, lung, and blood institute working group. Circulation 2010.
Wu W, Masri A, Popovic ZB, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: A cohort study. Circulation 2013.
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017.
Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: Colon cancer, version 2.2018. J Natl Compr Cancer Netw 2018.
Kirchmeyer M, Kalweit G, Gams E. Extended left pneumonectomy combined with off-pump coronary revascularization (CABG). Thorac Cardiovasc Surg 2000
Dyszkiewicz W, Jemielity MM, Piwkowski CT, et al. Simultaneous lung resection for cancer and myocardial revascularization without cardiopulmonary bypass (off-pump coronary artery bypass grafting). Ann Thorac Surg 2004.
Davydov MI, Akchurin RS, Gerasimov SS, et al. Simultaneous operations in thoraco-abdominal clinical oncology. Eur J Cardio-Thoracic Surg 2001.
Mariani MA, Van Boven WJ, Duurkens VAM, et al. Combined off-pump coronary surgery and right lung resections through midline sternotomy. Ann Thorac Surg 2001.
Fu Q, Li QZ, Liang DG, et al. Early and long-term results of combined cardiac surgery and neoplastic resection in patients with concomitant severe heart disease and neoplasms. Chin Med J (Engl) 2011.
Komokata T. Simultaneous operation for cardiac disease and gastrointestinal malignancy. World J Gastrointest Surg 2014.
Coimbra FJF, de Jesus VHF, Franco CP, et al. Predicting overall and major postoperative morbidity in gastric cancer patients. J Surg Oncol 2019.
Pandit V, Khan M, Martinez C, et al. A modified frailty index predicts adverse outcomes among patients with colon cancer undergoing surgical intervention. Am J Surg 2018.
Iyengar A, Goel N, Kelly JJ, et al. Effects of frailty on outcomes and 30-day readmissions after surgical mitral valve replacement. Ann Thorac Surg 2020.
Hackett NJ, De Oliveira GS, Jain UK, Kim JYS. ASA class is a reliable independent predictor of medical complications and mortality following surgery. Int J Surg 2015.
Alexander HR, Turnbull AD, Salamone J, et al. Upper abdominal cancer surgery in the very elderly. J Surg Oncol 1991.
Ahlgren JD. Gastrointestinal cancer in the elderly. Clin Geriatr Med 1999.
Balanescu SM, Balanescu DV, Donisan T, et al. The onco-cardiologist dilemma: to implant, to defer, or to avoid transcatheter aortic valve replacement in cancer patients with aortic stenosis? Curr Cardiol Rep 2019.
Greenfield LJ. Surgery of the aged. Management of respiratory problems. Major Probl Clin Surg 1975.
Stuck AE, Siu AL, Wieland GD, et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 1993.
PACE Participants, Audisio RA, Pope D, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 2008.
Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J 2015.
López J, Sevilla T, Vilacosta I, et al. Clinical significance of congestive heart failure in prosthetic valve endocarditis. A multicenter study with 257 patients. Rev Española Cardiol 2013.
Habib G, Tribouilloy C, Thuny F, et al. Prosthetic valve endocarditis: Who needs surgery? A multicentre study of 104 cases. Heart 2005.
Musci M, Weng Y, Hübler M, et al. Homograft aortic root replacement in native or prosthetic active infective endocarditis: Twenty-year single-center experience. J Thorac Cardiovasc Surg 2010.
Manne MB, Shrestha NK, Lytle BW, et al. Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. Ann Thorac Surg 2012.
Cahill TJ, Baddour LM, Habib G, et al. Challenges in Infective Endocarditis. J Am Coll Cardiol 2017.
Faggiano P, Frattini S, Zilioli V, et al. Prevalence of comorbidities and associated cardiac diseases in patients with valve aortic stenosis. Potential implications for the decision-making process. Int J Cardiol 2012.
Freemantle N, Irs A, De Paulis R, et al. Transcatheter versus surgical aortic valve replacement: What does the latest evidence tell us? Eur J Cardio-thoracic Surg 2019.
Popma JJ, Michael Deeb G, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019.
Donnellan E, Griffin BP, Johnston DR, et al. Rate of progression of aortic stenosis and its impact on outcomes in patients with radiation-associated cardiac disease: A matched cohort study. JACC Cardiovasc Imaging 2018.
Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013.
Guha A, Dey AK, Arora S, et al. Contemporary trends and outcomes of percutaneous and surgical aortic valve replacement in patients with cancer. J Am Heart Assoc 2020.
Schechter M, Balanescu DV, Donisan T, et al. An update on the management and outcomes of cancer patients with severe aortic stenosis. Catheter Cardiovasc Interv 2019.
Mangner N, Woitek FJ, Haussig S, et al. Impact of active cancer disease on the outcome of patients undergoing transcatheter aortic valve replacement. J Interv Cardiol 2018.
Nashef SAM, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardio-thoracic Surg 1999.
Shroyer ALW, Coombs LP, Peterson ED, et al. The society of thoracic surgeons: 30-Day operative mortality and morbidity risk models. Ann Thorac Surg 2003.
Danton MHD, Anikin VA, McManus KG, et al. Simultaneous cardiac surgery with pulmonary resection: Presentation of series and review of literature. Eur J Cardio-thoracic Surg 1998.
Negaard HFS, Iversen PO, Østenstad B, et al. Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost 2008.
Habib RH, Zacharias A, Engoren M. Determinants of prolonged mechanical ventilation after coronary artery bypass grafting. Ann Thorac Surg 1996.
Moshkovitz Y, Mohr R. Coronary artery bypass without cardiopulmonary-bypass - The pros and the cons. Isr J Med Sci 1993;29:716-20.
Tourmousoglou CE, Apostolakis E, Dougenis D. Simultaneous occurrence of coronary artery disease and lung cancer: what is the best surgical treatment strategy? Interact Cardiovasc Thorac Surg 2014.
Vieira RD, Pereira AC, Lima EG, et al. Cancer-related deaths among different treatment options in chronic coronary artery disease: Results of a 6-year follow-up of the MASS II study. Coron Artery Dis 2012.
Braile DM, Évora PRB. Cardiopulmonary bypass and cancer dissemination: A logical but unlikely association. Brazilian J Cardiovasc Surg 2018.
Zhu Y, Toth AJ, Lowry AM, et al. Cardiac surgery outcomes in patients with chronic lymphocytic leukemia. Ann Thorac Surg 2018.
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. In: WHO classification of tumours, Revised 4th Edition, Volume 2; 2017.
Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989.
Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: A consensus statement of major guidelines panels and call to action. J Clin Oncol 2009.
Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009.
Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009.
Di Nisio M, Ferrante N, Feragalli B, et al. Arterial thrombosis in ambulatory cancer patients treated with chemotherapy. Thromb Res 2011.
Clahsen PC, Van De Velde CJH, Julien JP, et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for research and treatment of cancer breast cancer cooperative group study. J Clin Oncol 1994.
Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988.
Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: Biological and clinical aspects. J Thromb Haemost 2013.
Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007.
Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013.
Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005.
Konstantinides SV, Meyer G, Bueno H, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J 2020.
Chang H-M, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy. J Am Coll Cardiol 2017.
Reeves BN, Key NS. PL-12 acquired hemophilia in malignancy. Thrombosis Res 2012.
Sallah S, Wan JY, Nguyen NP, et al. Disseminated intravascular coagulation in solid tumors: Clinical and pathologic study. Thromb Haemost 2001.
Kozwich DL, Kramer LC, Mielicki WP, et al. Application of cancer procoagulant as an early detection tumor marker. Cancer 1994.
Molnar S, Guglielmone H, Lavarda M, et al. Procoagulant factors in patients with cancer. Hematology 2007.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016.
Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. J Am Coll Cardiol 20142.
Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009.
Hildick-Smith D, Landmesser U, Camm AJ, et al. Left atrial appendage occlusion with the AmplatzerTM AmuletTM device: full results of the prospective global observational study. Eur Heart J 2020.
Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American heart association. Circulation 1997.
Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis. Am J Med 2008.
Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004.
Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-associated venous thromboembolic disease, Version 1.2015. J Natl Compr Cancer Netw 2015.
Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009.
Kaplan E. Venous thromboembolic disease. In: C.J. Wong, N.P. Hamli, editors. The perioperative medicine consult handbook. New York: Springer. 2015.
Khorana A, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy- associated thrombosis. Blood 2008.
- Abstract views: 60
- PDF: 27
Copyright (c) 2021 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.